One Shot, Five Organs: FGF21 Gene Therapy Extends Mouse Healthspan by 20%
A single AAV injection of FGF21 extended median lifespan by over 20% in aged mice, protecting liver, kidneys, heart, muscle, and brain — and it worked after age-related decline had already begun.
VERVE-102 and the Beginning of the End of Atherosclerosis
A Phase I trial published in the New England Journal of Medicine shows VERVE-102, a one-time base-editing gene therapy, can cut PCSK9 protein levels by up to 88% and LDL cholesterol by up to 62% — potentially permanently — in high-risk cardiovascular patients.
Scribe Therapeutics' STX-1150: Silencing PCSK9 Epigenetically Without Editing Your DNA
Scribe's STX-1150 cuts LDL 50%+ in primates for 18 months from a single dose — silencing PCSK9 epigenetically, not by altering the DNA sequence itself.
The Klotho Protocol: Architecting the Future of Cognitive Resilience
Klothea initiates the first longevity-focused human trial of mRNA-based klotho therapy, marking a shift from theoretical anti-aging to clinical bio-architecture.
Longevity Trials and Environmental Risks: Navigating the Future of Biohacking
Exploring the breakthrough Klotho therapy trials and the emerging threat of nanoplastics in the brain.